Another exciting breakthrough at Westlake 🧪
In @ScienceMagazine , Westlake researchers led by Bobo Dang and Ting Zhou (@tz4st ) developed a powerful new platform for engineering fast-acting covalent protein drugs.
From cancer to virus, the team created:
• IB101 – a PD-L1 antagonist with strong antitumor activity
• IB201 – boosting antitumor immunity
• A durable SARS-CoV-2 inhibitor
A big step toward next-gen covalent biologics with faster action and longer-lasting effects 🧬
Read the full article🔗 https://t.co/sS7Es58UII
#WestlakeUniversity #WhyWestlake #Research #Innovation #cancertreatment #drugdevelopment